DC
PLX icon

Diametric Capital’s Protalix BioTherapeutics PLX Stock Holding History

Diametric Capital’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$270K Sell
124,195
-14,734
-11% -$36.6K 0.07% 354
2025
Q4 		$250K Sell
138,929
-41,055
-23% -$83.9K 0.07% 326
2025
Q3 		$400K Buy
179,984
+36,712
+26% +$59.8K 0.15% 183
2025
Q2 		$212K Buy
+143,272
New +$293K 0.11% 250

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Diametric Capital's PLX Position: Q1 2026 in Review

Diametric Capital reduced its Protalix BioTherapeutics (PLX) stake by 11% in Q1 2026, selling an estimated $36.6K and leaving 124,195 shares worth $270K. The position accounts for 0.07% of the portfolio, ranked #354.

Diametric Capital first reported a position in PLX in Q2 2025 and has held it in 4 quarters since. The position peaked at $400K in Q3 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Diametric Capital held 124,195 shares of Protalix BioTherapeutics worth $270K as of Q1 2026.
  • Diametric Capital sold 14,734 Protalix BioTherapeutics shares in Q1 2026, an estimated $36.6K.
  • Protalix BioTherapeutics made up 0.07% of Diametric Capital's portfolio in Q1 2026, its #354 holding.
  • Diametric Capital first reported a position in Protalix BioTherapeutics in Q2 2025 and has held it in 4 quarters since.
  • Diametric Capital's Protalix BioTherapeutics position peaked at $400K in Q3 2025.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Diametric Capital's 13F filing for Q1 2026, filed 15 May 2026.